Skip to content
value.today

Cingulate Inc.

CING
$83 Mmarket cap on Oct 28, 2026+934.4% since Jan 2024
Compare
World rank
#19,456
Revenue
—
For year ending December-2025
Net income
$-22 M
SEC filing
Employees
—

Cingulate Inc. in brief

Cingulate Inc. is a listed company in the Biotechnology industry, based in Kansas City, Kansas, USA. Its market value was $83 M on 28 October 2026, which makes it the 19,456th largest listed company in the world and the 3,622nd largest in the USA on this site. Shane J. Schaffer is its chief executive. Its shares trade under the symbol CING (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cingulate Inc.

We are a biopharmaceutical company using our proprietary Precision Timed ReleaseTM drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder and anxiety, we are identifying and evaluating additional therapeutic areas where our PTR technology may be employed to develop future product candidates. Our PTR platform incorporates a proprietary Erosion Barrier Layer designed to allow for the release of drug substance at specific, pre-defined time intervals, unlocking the potential for once-daily, multi-dose tablets.

From the company's annual report filed with the US SEC: read the report

Cingulate Inc. timeline

2 events, 2021
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 9 December 2021; shares registered for exchange trading on 3 December 2021.

Events of Cingulate Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$22 M$45 M$67 M$89 M2023202420252026

World rank over time

▲ up 11,776 places since 2022
2022-12-25: #31279#31,27920222023-07-30: #32660#32,66020232024-01-05: #31505#31,50520242026-03-08: #10493#10,49320262026-08-01: #18508#18,50820262026-10-13: #20033#20,03320262026-10-28: #19503#19,5032026

Rank in USA: #5,529 (Dec 2022) · #5,575 (Jul 2023) · #4,557 (Jan 2024) · #2,048 (Mar 2026) · #3,613 (Aug 2026) · #3,671 (Oct 2026) · #3,626 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
33.0×
Free cash flow yield
-21.0%
Net margin
—
Operating margin
—
Return on equity
-894.4%
Liabilities / assets
83.3%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-7M—FY20Fiscal year ending Dec 2021: revenue —, net income $-21M—FY21Fiscal year ending Dec 2022: revenue —, net income $-18M—FY22Fiscal year ending Dec 2023: revenue —, net income $-24M—FY23Fiscal year ending Dec 2024: revenue —, net income $-17M—FY24Fiscal year ending Dec 2025: revenue —, net income $-22M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-20M$-22M—
Dec 2024——$-16M$-17M—
Dec 2023——$-23M$-24M—
Dec 2022——$-18M$-18M—
Dec 2021——$-21M$-21M—
Dec 2020——$-7M$-7M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-17M$0M$-17M$-4.44—
Dec 2024$-18M$0M$-19M$-10.86—
Dec 2023$-15M$0M$-15M$-311.99—
Dec 2022$-16M$0M$-16M$-29.35—
Dec 2021$-10M$1M$-11M$-2.79—
Dec 2020$-7M$0M$-7M——

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-6M—Dec ’24Three months to Mar 2025: revenue —, net income $-4M—Mar ’25Three months to Jun 2025: revenue —, net income $-5M—Jun ’25Three months to Sep 2025: revenue —, net income $-7M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-6M—Dec ’25Three months to Mar 2026: revenue —, net income $-9M—Mar ’26Three months to Jun 2026: revenue —, net income $-6M—Jun ’26Three months to Sep 2026: revenue —, net income $-8M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Cingulate Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-20 M
Net income
$-22 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$15 M
Total liabilities
$13 M
Total equity
$3 M

As of December-2025

Top 41 institutional investors in Cingulate Inc.#

As of Sep 30, 2026
41 institutions held 2.9 M shares (about 19.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 14.4%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Cingulate Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC570,8730 (0.00%)3.93%$3 MNov 13, 2026
2Susquehanna International Group, LLP223,866New1.54%$1 MNov 16, 2026
3Raymond James Financial Inc214,898+48,000 (+28.76%)1.48%$1 MNov 12, 2026
4Renaissance Technologies LLC186,384+58,884 (+46.18%)1.28%$1 MNov 12, 2026
5Citadel Advisors LLC176,930New1.22%$1 MNov 16, 2026
6Marshall Wace, LLP160,380New1.10%$1 MNov 13, 2026
7Kestra Advisory Services, LLC156,500+5,000 (+3.30%)1.08%$1 MNov 2, 2026
8Geode Capital Management, LLC152,820+8,184 (+5.66%)1.05%$1 MNov 6, 2026
9Bolton Securities Corporation139,0000 (0.00%)0.96%$1 MNov 12, 2026
10Chicago Partners Investment Group LLC110,737-77,692 (-41.23%)0.76%$1 MOct 27, 2026
11North Star Investment Management Corp.100,000New0.69%$0 MOct 27, 2026
12Vanguard Fiduciary Trust Co88,831+9,671 (+12.22%)0.61%$0 MNov 13, 2026
13Simplex Trading, LLC70,978New0.49%$0 MNov 4, 2026
14UBS Group AG68,970+43,023 (+165.81%)0.47%$0 MNov 10, 2026
15BlackRock, Inc.54,506+1,376 (+2.59%)0.37%$0 MNov 13, 2026
16State Street Corp52,188+4,300 (+8.98%)0.36%$0 MNov 12, 2026
17BCV Asset Management Inc.51,2000 (0.00%)0.35%$0 MNov 6, 2026
18Captrust Financial Advisors42,123New0.29%$0 MNov 12, 2026
19Northern Trust Corp35,226+105 (+0.30%)0.24%$0 MNov 16, 2026
20Prospera Financial Services Inc32,250+2,350 (+7.86%)0.22%$0 MNov 4, 2026
21Quantum Private Wealth, LLC30,0000 (0.00%)0.21%$0 MOct 20, 2026
22Bank Of America Corp /de/27,329New0.19%$0 MNov 16, 2026
23Mariner, LLC23,140+1,859 (+8.74%)0.16%$0 MNov 12, 2026
24Jane Street Group, LLC21,620-7,258 (-25.13%)0.15%$0 MNov 12, 2026
25Spark Investment Management LLC20,400New0.14%$0 MNov 13, 2026
Show all 41: investors 26 to 41
Institutional investors 26 to 41 in Cingulate Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26PKS Advisory Services, LLC11,5000 (0.00%)0.08%$0 MOct 26, 2026
27Vanguard Global Advisers, LLC4,7430 (0.00%)0.03%$0 MNov 13, 2026
28Morgan Stanley3,924-339 (-7.95%)0.03%$0 MNov 13, 2026
29Group One Trading LLC3,672New0.03%$0 MNov 10, 2026
30Barclays PLC3,130+1,564 (+99.87%)0.02%$0 MNov 6, 2026
31Root Financial Partners, LLC2,500New0.02%$0 MOct 21, 2026
32Jones Financial Companies Lllp2,364+364 (+18.20%)0.02%$0 MNov 13, 2026
33Wells Fargo & Company/mn2,342+1,342 (+134.20%)0.02%$0 MNov 16, 2026
34Harbour Investments, Inc.2,275New0.02%$0 MNov 9, 2026
35IFP Advisors, Inc2,0000 (0.00%)0.01%$0 MOct 16, 2026
36Tower Research Capital LLC (TRC)614+140 (+29.54%)0.00%$0 MNov 16, 2026
37Royal Bank Of Canada295New0.00%$0 MNov 16, 2026
38Rialto Wealth Management, LLC1020 (0.00%)0.00%$0 MNov 16, 2026
39Caitong International Asset Management Co., Ltd8New0.00%$0 MOct 29, 2026
40FMR LLC6New0.00%$0 MNov 10, 2026
41SBI Securities Co., Ltd.10 (0.00%)0.00%$0 MOct 22, 2026

Mutual funds holding Cingulate Inc.#

11 funds hold shares worth $4 M (about 4.7% of the company). Since their previous reports 10 added shares and 0 sold, buying $2 M net.
Mutual funds holding Cingulate Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.394,555$2 M2.7%<0.01%+86%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.160,396$1 M1.1%<0.01%+75%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC42,839$0 M0.29%<0.01%+14%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors27,990$0 M0.19%0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC22,533$0 M0.15%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.10,246$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC10,991$0 M0.08%<0.01%+40%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC8,474$0 M0.06%<0.01%newMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.5,676$0 M0.04%<0.01%+1.4%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,871$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC246$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 11 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Cingulate Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$657 K
5 purchases, 5 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$657 K
open market only
Insiders on file
12
since
$657 K-$842$0Aug 2024: bought $0 (0 trades), sold $842 (1 trades)Aug 24Feb 2026: bought $657 K (5 trades), sold $0 (0 trades)Feb
Bought (open market)Sold (open market)Hover a month for the totals
Cingulate Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Raul R. SilvaEVP and CSOGrant or award+4,526——6,473Form 4
filed Matthew BramsEVP and Chief Medical OfficerGrant or award+4,526——9,182Form 4
filed Nilay Dahyabhai PatelEVP, CLO and CCOGrant or award+5,475——5,475Form 4
filed Jennifer L. CallahanEVP and CFOGrant or award+15,329——20,388Form 4
filed Shane J. SchafferChief Executive Officer, DirectorGrant or award+6,862——7,035Form 4
filed Nilay Dahyabhai PatelEVP, CLO and CCOShares withheld for tax-2,086——3,389Form 4
filed Matthew BramsEVP and Chief Medical OfficerShares withheld for tax-1,025——8,157Form 4
filed Jennifer L. CallahanEVP and CFOShares withheld for tax-6,427——13,961Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Cingulate Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.0 M
14.3% of shares · 7.52 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-06-02 13:34 UTC, code LUDP, resumed 13:39 UTC
  • 2026-06-02 11:55 UTC, code T3, resumed 12:30 UTC

Fails to deliver

  • : 1,460 shares at $5.53
  • : 3,646 shares at $4.36
  • : 35 shares at $4.84
  • : 1 shares at $4.75
  • : 800 shares at $4.76

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cingulate Inc. scorecard#

Passes 1 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median33.0×Price to book 33.0× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-21.0%Free cash flow is -21.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-4.44 vs -10.86Diluted EPS -4.44 in fiscal 2025 against -10.86 the year before (report's currency).
    • ✗Net income higher than five years earlier-$22 M-$22 M in fiscal 2025 against -$7 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-450.4%-450.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.2×Current ratio 1.16 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-22.2×Operating income -22.2 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year231.5%Diluted shares up 231.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Cingulate Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cingulate Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Research and development9.89.4159.08.45.1
General and administrative106.27.38.5122.0
Operating income−20−16−23−18−21−7.1
Interest expense and finance costs0.90.00.80.30.00.1
Net interest income−1.40.1————
Other non-operating income (expense)—0.1−0.8−0.2−0.0−0.1
Income before tax−22−17r−24−18−21−7.2
Net income attributable to shareholders−22−17r−24−18−21−7.2
Earnings per share, basic-4.44-10.86r-311.99r-29.35r-2.79—
Earnings per share, diluted-4.44-10.86r-311.99r-29.35-2.79—
Shares, weighted average (basic)5.11.50.1r0.6r7.4—
Shares, weighted average (diluted)5.11.50.1r0.67.4—
Balance sheet
Cash and cash equivalents11120.15.4161.2
Short-term investments————0.00.0
Receivables——0.0———
Other current assets1.00.40.52.31.70.4
Current assets12130.67.9191.8
Property, plant and equipment1.72.12.52.93.13.0
Right-of-use (leased) assets1.30.10.40.60.91.0
Total assets15153.511235.8
Accounts payable2.01.35.2r0.80.31.0
Current liabilities105.0107.01.23.4
Lease liabilities (non-current)1.1—0.10.50.81.1
Non-current liabilities2.32.40.10.50.9—
Total liabilities137.4107.52.04.5
Retained earnings−132−110r−93−69−52−31
Shareholders' equity2.57.5−6.93.9211.3r
Total liabilities and equity15153.511235.8
Shares outstanding7.33.40.1r0.6r11—
Cash-flow statement
Share-based compensation1.51.00.80.80.0—
Cash from operating activities−17−18−15−16−10−6.8
Capital expenditure−0.2−0.2−0.2−0.2−0.8−0.4
Cash from investing activities−0.2−0.2−0.2−0.2−0.8−0.4
Shares issued10267.0—20—
Cash from financing activities163110.04.9278.0
Change in cash−1.312−5.3−1115—
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Cingulate Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 11 · Material agreement 3 · New debt 1 · Unregistered share sale 6 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 5

Cingulate Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Material agreementShareholder vote8-K
Results announced8-K
Directors and officersUnregistered share sale8-K
Unregistered share sale8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Unregistered share sale8-K
Directors and officers8-K
Results announced8-K
Material agreementNew debt8-K
Shareholder vote8-K
Unregistered share sale8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Unregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 2, 2026

How Cingulate Inc. compares in Biotechnology

  • Market cap$83 M · higher than 33% of 726
  • Price / book33.0× · lower than 5% of 534
  • FCF yield-21.0% · higher than 43% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cingulate Inc.🇺🇸$83 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cingulate Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cingulate Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cingulate Inc.? Suggest a correction